Genetic prostate cancer screening study aims to catch tumors early

NCT ID NCT00261456

Ongoing Knowledge-focused Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

The IMPACT study is an international effort to screen men aged 40-69 who carry BRCA1, BRCA2, or mismatch repair gene mutations, which raise their risk of prostate cancer. Participants receive annual PSA tests and optional biopsies if levels are high. The goal is to learn how often prostate cancer is found in these men compared to those without the mutations, and to improve early detection strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could show that annual PSA screening helps detect prostate cancer earlier in men with certain gene mutations, potentially leading to better outcomes.
What could go wrong: This is an observational screening study, not a treatment trial. It may not prove that screening saves lives, and results may not apply to all men.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis inherited disease susceptibility prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA MUTATION GENETIC PREDISPOSITION TO DISEASE MISMATCH REPAIR GENE MUTATION PROSTATE CANCER

Contacts and locations

Locations

Cancer Genetics Unit, Royal Marsden Hospital

Sutton, Surrey, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.